PT2087002E - Composições e métodos para a ligação de esfingosina-1- fosfato - Google Patents

Composições e métodos para a ligação de esfingosina-1- fosfato Download PDF

Info

Publication number
PT2087002E
PT2087002E PT78712627T PT07871262T PT2087002E PT 2087002 E PT2087002 E PT 2087002E PT 78712627 T PT78712627 T PT 78712627T PT 07871262 T PT07871262 T PT 07871262T PT 2087002 E PT2087002 E PT 2087002E
Authority
PT
Portugal
Prior art keywords
phosphate
compositions
methods
binding sphingosine
sphingosine
Prior art date
Application number
PT78712627T
Other languages
English (en)
Portuguese (pt)
Inventor
Roger A Sabbadini
William A Garland
Genevieve Hansen
Steven Tarran Jones
David Gareth Williams
Original Assignee
Lpath Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath Inc filed Critical Lpath Inc
Publication of PT2087002E publication Critical patent/PT2087002E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT78712627T 2006-10-27 2007-10-26 Composições e métodos para a ligação de esfingosina-1- fosfato PT2087002E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85497106P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
PT2087002E true PT2087002E (pt) 2014-11-26

Family

ID=39492938

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78712627T PT2087002E (pt) 2006-10-27 2007-10-26 Composições e métodos para a ligação de esfingosina-1- fosfato

Country Status (18)

Country Link
US (6) US7829674B2 (enExample)
EP (1) EP2087002B1 (enExample)
JP (2) JP5795833B2 (enExample)
KR (1) KR101581279B1 (enExample)
CN (2) CN101679506B (enExample)
AU (1) AU2007329759B2 (enExample)
BR (1) BRPI0718118A2 (enExample)
CA (1) CA2667574A1 (enExample)
DK (1) DK2087002T3 (enExample)
ES (1) ES2524059T3 (enExample)
IL (1) IL198379A (enExample)
MX (1) MX2009004532A (enExample)
PL (1) PL2087002T3 (enExample)
PT (1) PT2087002E (enExample)
RU (1) RU2460541C2 (enExample)
SI (1) SI2087002T1 (enExample)
WO (1) WO2008070344A2 (enExample)
ZA (1) ZA200902860B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
EP2262528A2 (en) * 2008-02-25 2010-12-22 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
KR20110097923A (ko) * 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
KR101844859B1 (ko) 2009-08-06 2018-05-18 제넨테크, 인크. 단백질 정제 시의 바이러스 제거의 개선방법
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
WO2011109650A1 (en) * 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
EP2563395A4 (en) * 2010-04-30 2013-11-27 Lpath Inc TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
US20130344087A1 (en) * 2010-06-06 2013-12-26 Roger A. Sabbadini Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012072715A2 (en) * 2010-12-01 2012-06-07 Universität Zürich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
JP5766958B2 (ja) * 2011-01-21 2015-08-19 オリンパス株式会社 顕微鏡システム、情報処理装置、及び情報処理プログラム
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
WO2013027034A1 (en) 2011-08-19 2013-02-28 Malvern Instruments Limited Dual-mode characterization of particulates
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
KR102090849B1 (ko) * 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
JP6602304B2 (ja) 2014-01-03 2019-11-06 エフ.ホフマン−ラ ロシュ アーゲー 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
EP3215246B1 (en) * 2014-11-06 2024-08-07 Merck Patent GmbH A method for the removal of leachables and/or extractables
US9754383B1 (en) * 2014-12-22 2017-09-05 Flagship Biosciences, Inc. Automated methods for assessment of celiac disease
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CN109328018A (zh) 2016-12-15 2019-02-12 雀巢产品技术援助有限公司 调节伴侣动物体内的磷或酶的组合物和方法
WO2018191751A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1073471B (de) 1958-09-02 1960-01-21 Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) Verfahren zur Herstellung von Azelainsäure
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
SE455445B (sv) 1984-08-28 1988-07-11 Pharmacia Ab Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik
EP0173648A3 (en) 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE3741056A1 (de) 1987-12-04 1989-08-24 Behringwerke Ag Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5248824A (en) 1990-12-31 1993-09-28 The Biomembrane Institute Method of preparing N,N,N-trimethylsphingosine
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5137919A (en) 1990-12-31 1992-08-11 Biomembrane Institute Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5677288A (en) 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5260288A (en) 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
WO1995013818A1 (en) 1993-11-15 1995-05-26 Baker Medical Research Institute A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
EP1008342A3 (en) 1994-02-02 2004-12-29 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5585476A (en) 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5667337A (en) 1995-09-15 1997-09-16 Lazes; Richard J. Rotating containment and repelling boom and method for confining a material floatable on a liquid surface
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JPH09110722A (ja) 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (de) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
EP0940409B1 (en) 1996-07-19 2004-05-12 Takara Shuzo Co. Ltd. Process for the preparation of sphingolipids and sphingolipid derivatives
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6140060A (en) 1996-12-12 2000-10-31 Chun; Jerold J. M. Cloned lysophosphatidic acid receptors
US5919687A (en) 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
US6235912B1 (en) 1997-03-12 2001-05-22 Takara Shuzo Co., Ltd. Sphingosine analogues
CA2293718A1 (en) 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US6740512B1 (en) 1997-08-11 2004-05-25 Memorec Biotec Gmbh Neutral sphingomyelinase
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AU9002298A (en) 1997-09-11 1999-03-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6057126A (en) 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
JP2002501751A (ja) 1998-01-29 2002-01-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
AU765809B2 (en) 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
DE69827043D1 (de) 1998-02-16 2004-11-18 Kitasato Inst Neue verbindungen kf-1040 und verfahren zu ihrer herstellung
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6130067A (en) 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
AU4097999A (en) 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
DE19828850A1 (de) 1998-06-27 1999-12-30 Gvs Ges Fuer Erwerb Und Verwer Sphingolipid-Desaturase
DK1091745T3 (da) 1998-06-29 2008-12-15 Los Angeles Childrens Hospital Behandling af hyperproliferative forstyrrelser
DE19847149A1 (de) 1998-10-13 2000-04-20 Max Planck Gesellschaft Pseudo-Ceramide
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
WO2000040262A1 (en) 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
AU2899900A (en) 1999-03-02 2000-09-21 Nps Allelix Corp. Cloned human sphingosine kinase homologues
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
US6608185B1 (en) 1999-03-25 2003-08-19 Kitasato Institute Substances KF-1040T4A,KF-1040T4B, KF-1040T5A, and KF-1040T5B, and process for producing same
JP3995420B2 (ja) 1999-03-26 2007-10-24 タカラバイオ株式会社 セラミダーゼ遺伝子
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
JP2000293181A (ja) 1999-04-12 2000-10-20 Daiichikosho Co Ltd 歌詞画像描出機能に特徴を有するカラオケ装置
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
WO2000070028A1 (en) 1999-05-13 2000-11-23 Johnson & Johnson Research Pty. Limited Sphingosine kinase enzyme
DE19924148A1 (de) 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinasehemmer
WO2001004139A2 (en) 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
IT1307786B1 (it) 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
CA2389127A1 (en) 1999-10-28 2001-05-03 Warner-Lambert Company Human sphingosine kinase gene
WO2001038295A1 (fr) 1999-11-24 2001-05-31 Taisho Pharmaceutical Co.,Ltd. Derives de sphingosine
WO2001055410A2 (en) 2000-01-28 2001-08-02 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
CA2399683A1 (en) 2000-02-07 2001-08-09 Merck & Co., Inc. Mammalian sphingosine-1-phosphate phosphatase
AU3828301A (en) 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US20020037495A1 (en) 2000-03-23 2002-03-28 Gutierrez Juan Antonio High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
WO2001072701A1 (en) 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
AU2001255477A1 (en) 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
US20030125533A1 (en) 2000-10-06 2003-07-03 Sophia Kossida Regulation of human sphingosine kinase-like protein
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020150582A1 (en) 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2006014802A2 (en) * 2004-07-27 2006-02-09 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 1
ES2410866T3 (es) * 2004-10-28 2013-07-03 Lpath, Inc. Composiciones y procedimientos para el tratamiento y prevención de enfermedades hiperproliferativas
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions

Also Published As

Publication number Publication date
US8222373B2 (en) 2012-07-17
RU2009120052A (ru) 2010-12-10
US20090010922A1 (en) 2009-01-08
WO2008070344A2 (en) 2008-06-12
JP2010515427A (ja) 2010-05-13
AU2007329759A1 (en) 2008-06-12
AU2007329759B2 (en) 2013-05-30
CN104650225B (zh) 2019-10-01
MX2009004532A (es) 2009-09-04
US7956173B2 (en) 2011-06-07
US20100003242A1 (en) 2010-01-07
JP6053834B2 (ja) 2016-12-27
IL198379A0 (en) 2011-08-01
SI2087002T1 (sl) 2014-11-28
CA2667574A1 (en) 2008-06-12
EP2087002B1 (en) 2014-09-24
US20090130100A1 (en) 2009-05-21
CN101679506A (zh) 2010-03-24
ZA200902860B (en) 2010-07-28
JP5795833B2 (ja) 2015-10-14
BRPI0718118A2 (pt) 2017-05-30
US8026342B2 (en) 2011-09-27
KR20100043137A (ko) 2010-04-28
JP2015134760A (ja) 2015-07-27
CN101679506B (zh) 2015-02-25
US20090137037A1 (en) 2009-05-28
US7829674B2 (en) 2010-11-09
DK2087002T3 (da) 2014-10-27
IL198379A (en) 2015-04-30
ES2524059T3 (es) 2014-12-03
US20090130099A1 (en) 2009-05-21
US20090148443A1 (en) 2009-06-11
RU2460541C2 (ru) 2012-09-10
KR101581279B1 (ko) 2015-12-31
US8067549B2 (en) 2011-11-29
US8025877B2 (en) 2011-09-27
CN104650225A (zh) 2015-05-27
EP2087002A2 (en) 2009-08-12
WO2008070344A3 (en) 2008-11-20
EP2087002A4 (en) 2010-06-30
PL2087002T3 (pl) 2015-02-27
WO2008070344A9 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ZA200902860B (en) Compositions and methods for binding sphingosine-1-phosphate
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP2164992A4 (en) COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2035014A4 (en) FUCOIDANE PREPARATIONS AND METHODS
EP2041267A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE USE OF GLYCEROL
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
EP2046936A4 (en) BIOCIDAL COMPOSITIONS AND METHODS
IL198651A0 (en) COMPOSITION COMPRISING (-)-Ôêå9-TRANS-TETRAHYDROCANNABIONOL
PL1988081T3 (pl) Inhibitor wiązania sfingozyno-1-fosforanu
GB0721291D0 (en) Methods and compositions
IL205248A0 (en) Compositions and methods for making androstenediones
EP2205271A4 (en) COMPOSITIONS AND METHODS OF THERAPIES BASED ON RIBONUCLEASE BASE
GB0719526D0 (en) Compositions and methods
GB0607605D0 (en) Composition
GB0617171D0 (en) Novel compositions and methods
EP2034019A4 (en) COMPOSITION FOR THE NUCLEENIC ACID INTRODUCTION
EP2183380A4 (en) METHODS AND COMPOSITIONS FOR PCR
GB0625230D0 (en) Compositions and methods
GB0616269D0 (en) Methods and compositions
GB0607565D0 (en) Methods and compositions
GB0724549D0 (en) Compositions and methods
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods
GB0625144D0 (en) Novel binding agents